Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00798915 · ClinicalTrials.gov registry record · Phase 1
Study of the Effects of Xenin-25 in Humans With and Without Type 2 Diabetes Mellitus
A Phase 1 study, sponsored by Washington University School of Medicine.
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
NCT00798915: Completed Phase 1 study, sponsored by Washington University School of Medicine.
NCT00798915 is a Phase 1 study that has completed, run by Washington University School of Medicine. The registered enrollment target is 40 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (33% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00798915, a Phase 1 study, has completed, sponsored by Washington University School of Medicine.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
Study Summary
An intestinal hormone called Glucose-dependent Insulinotropic Polypeptide (GIP) is released into the blood immediately after ingestion of a meal and plays an important role in regulating blood sugar levels. However, GIP is not active in persons with type 2 diabetes mellitus (T2DM) which is also known as adult onset or non-insulin-dependent diabetes. This study is being conducted to determine whether a hormone called xenin-25 can restore the activity of GIP in persons with T2DM.
Interventions
- DRUG Placebo
- DRUG Glucose-dependent Insulinotropic Polypeptide (GIP)
- DRUG Xenin-25
- DRUG Glucose-dependent Insulinotropic Polypeptide plus Xenin-25
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2008-12 |
| Est. Completion | 2012-12 |
| Phase | Phase 1 |
What the finished NCT00798915 record still lists
NCT00798915 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (33% lower).
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT00798915 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00798915 about?
NCT00798915 is a clinical study titled "Study of the Effects of Xenin-25 in Humans With and Without Type 2 Diabetes Mellitus". An intestinal hormone called Glucose-dependent Insulinotropic Polypeptide (GIP) is released into the blood immediately after ingestion of a meal and plays an important role in regulating blood sugar levels. However, GIP is not active in persons with type 2 diabetes mellitus (T2DM) which is also know...
What is the current status of trial NCT00798915?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2008-12. Estimated completion is 2012-12.
What interventions are being tested in trial NCT00798915?
The interventions under investigation include: Placebo (DRUG), Glucose-dependent Insulinotropic Polypeptide (GIP) (DRUG), Xenin-25 (DRUG), Glucose-dependent Insulinotropic Polypeptide plus Xenin-25 (DRUG).
Who is sponsoring clinical trial NCT00798915?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00798915's enrollment target sits among peer trials
40 1130th of 2000 higher than 810 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia